1294512-27-8

Usage

Uses

Used in Pharmaceutical Industry:
3-(1,1-difluoroallyl)quinoxalin-2-ol is used as an antiviral agent for its potential to combat viral infections, particularly those caused by hepatitis C virus. Its antiviral activity makes it a valuable compound in the development of treatments for viral diseases.
Additionally, it serves as a crucial intermediate in the synthesis of Glecaprevir, which is used as a direct-acting antiviral drug. This application is significant in the pharmaceutical industry, as it contributes to the production of medications that can effectively manage and treat chronic hepatitis C.

Upstream product

• 1365970-40-6 C₇H₁₀F₂O₃ 
• 1294512-26-7 ethyl 3,3-difluoro-2-oxopent-4-enoate 
• 95-54-5 1,2-diamino-benzene 

Downstream Products

• 1365970-48-4 C₂₉H₃₄F₂N₄O₇ 

Relevant academic research and scientific papers

Development of the Enabling Route for Glecaprevir via Ring-Closing Metathesis

Glecaprevir was identified as a potent HCV NS3/4A protease inhibitor, and an enabling synthesis was required to support the preclinical evaluation and subsequent Phase I clinical trials. The enabling route to glecaprevir was established through further development of the medicinal chemistry route. The key steps in the synthesis involved a ring-closing metathesis (RCM) reaction to form the 18-membered macrocycle and a challenging fluorination step to form a key amino acid. The enabling route was successfully used to produce 41 kg of glecaprevir, sufficient to support the preclinical evaluation and early clinical development.

Synthetic route to anti-viral agents

The invention provides methods of synthesizing a viral protease inhibitor in high yield, without using expensive catalysts or challenging reaction conditions.

Macrocyclic proline derived HCV serine protease inhibitors

The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the com

BISMACROKYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS

The present invention discloses compounds of formula (Ia) or (Ib) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequent